1、PRESSRELEASEAbbVieReportsFirst-Quarter2025FinancialResultsReportsFirst-QuarterDilutedEPSof$0.72onaGAAPBasis,aDecreaseof6.5Percent;AdjustedDilutedEPSof$2.46,anIncreaseof6.5Percent;TheseResultsIncludeanUnfavorableImpactof$0.13PerShareRelatedtoAcquiredIPR&DandMilestonesExpenseDeliversFirst-QuarterNetRe
2、venuesof$13.343Billion,anIncreaseof8.4PercentonaReportedBasisor9.8PercentonanOperationalBasisFirst-QuarterGlobalNetRevenuesfromtheImmunologyPortfolioWere$6.264Billion,anIncreaseof16.6PercentonaReportedBasis,or18.1PercentonanOperationalBasis;GlobalSkyriziNetRevenuesWere$3.425Billion;GlobalRinvoqNetRe
3、venuesWere$1.718Billion;GlobalHumiraNetRevenuesWere$1.121BillionFirst-QuarterGlobalNetRevenuesfromtheNeurosciencePortfolioWere$2.282Billion,anIncreaseof16.1PercentonaReportedBasis,or17.0PercentonanOperationalBasis;GlobalVraylarNetRevenuesWere$765Million;GlobalBotoxTherapeuticNetRevenuesWere$866Milli
4、on;CombinedGlobalUbrelvyandQuliptaNetRevenuesWere$433MillionFirst-QuarterGlobalNetRevenuesfromtheOncologyPortfolioWere$1.633Billion,anIncreaseof5.8PercentonaReportedBasis,or7.5PercentonanOperationalBasis;GlobalImbruvicaNetRevenuesWere$738Million;GlobalVenclextaNetRevenuesWere$665Million;GlobalElaher
5、eNetRevenuesWere$179MillionFirst-QuarterGlobalNetRevenuesfromtheAestheticsPortfolioWere$1.102Billion,aDecreaseof11.7PercentonaReportedBasis,or10.2PercentonanOperationalBasis;GlobalBotoxCosmeticNetRevenuesWere$556Million;GlobalJuvedermNetRevenuesWere$231MillionRaises2025AdjustedDilutedEPSGuidanceRang
6、efrom$11.99-$12.19to$12.09-$12.29,whichIncludesanUnfavorableImpactof$0.13PerShareRelatedtoAcquiredIPR&DandMilestonesExpenseIncurredYear-To-DateThroughtheFirstQuarter2025NORTHCHICAGO,Ill.,April25,2025AbbVie(NYSE:ABBV)announcedfinancialresultsforthefirstquarterendedMarch31,2025.AbbViesfirst-quarterres